Geode Capital Management LLC Has $5.53 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Geode Capital Management LLC grew its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,523,971 shares of the biopharmaceutical company’s stock after buying an additional 273,436 shares during the quarter. Geode Capital Management LLC’s holdings in Lexicon Pharmaceuticals were worth $5,534,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in LXRX. CVI Holdings LLC acquired a new stake in Lexicon Pharmaceuticals in the 2nd quarter valued at about $34,000. Principal Financial Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 12,225 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at approximately $50,000. BNP Paribas Financial Markets raised its position in Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,246 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 23,893 shares in the last quarter. 74.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. Finally, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Trading Up 1.5 %

NASDAQ:LXRX opened at $0.79 on Friday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.62 and a 1-year high of $3.73. The firm has a market capitalization of $194.18 million, a price-to-earnings ratio of -1.05 and a beta of 1.06. The business’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.49.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period in the previous year, the business earned ($0.21) EPS. On average, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.